The Relationship between TP53 Gene Status and Carboxylesterase 2 Expression in Human Colorectal Cancer.

doi:10.1155/2018/5280736

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The Relationship between TP53 Gene Status and Carboxylesterase 2 Expression in Human Colorectal Cancer.

Disease markers - 1 Jan 2018

Ishimine Momoko, Lee Hyeon-Cheol, Nakaoka Hirofumi, Orita Hajime, Kobayashi Toshiyuki, Mizuguchi Konomi, Endo Mikumi, Inoue Ituro, Sato Koichi, Yokomizo Takehiko

Abstract excerpt

Irinotecan (CPT-11) is an anticancer prodrug that is activated by the carboxylesterase CES2 and has been approved for the treatment of many types of solid tumors, including colorectal cancer. Recent studies with cell lines show that CES2 expression is regulated by the tumor suppressor protein p53. However, clinical evidence for this regulatory mechanism in cancer is lacking. In this study, we examined the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboxylesterase
Share to Cell Line, Tumor
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Down-Regulation

Share to Gene Expression Regulation, Neoplastic

Share to HCT116 Cells

Share to Sequence Analysis, DNA

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 29651325
DOI: 10.1155/2018/5280736
PMCID: PMC5831679

Genes

CES2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.